慢性阻塞性肺疾病的发病机制和临床药物研究进展被引量：38

Advance in Pathological Research and Pharmacological Therapies of Chronic Obstructive Pulmonary Disease

下载PDF

导出

摘要慢性阻塞性肺疾病(COPD)作为一个发病率越来越高的健康杀手,其发病机制被认为与肺脏因吸入有害气体或颗粒而引起的异常炎症反应有关。用于治疗COPD的药物包括支气管扩张剂和抗炎药物,目前多种长效支气管扩张剂及其复方制剂正在进行临床研究。本文对COPD的发病机制和临床药物进展作一综述。 Chronic obstructive pulmonary disease （COPD） is a major global health problem with a rising incidence. The pathogenesis of this disease is associated with abnormal inflammatory immune responses of the lung to noxious particles and gases. Several long acting inhaled bronchodilators, anti-inflammatory drugs and their combinations are now in development. This review summarizes the pathological mechanisms of COPD and therapeutic agents in clinical development.

作者向左娟孙宏斌

机构地区中国药科大学新药研究中心

出处《药学与临床研究》 2013年第1期47-56,共10页 Pharmaceutical and Clinical Research

关键词慢性阻塞性肺疾病发病机制气管扩张剂抗炎药物复方制剂 Chronic obstructive pulmonary disease Pathogenesis Bronchodilators Anti-inflammatory drugs Combinations

分类号 R563 [医药卫生—呼吸系统] R974 [医药卫生—药品]

引文网络
相关文献

参考文献66

1Rabe KF, Hurd S, Anzueto A, et al. Global strategy fin" the diagnosis, management, and prevention of chronic obstnwtive pulmona~" disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2007, 176(6): 532-55.
2Hui CKM, Chung KF. Indacateroh pharmacologic pro- file. efficacy and safety in the treatment of adults with COPD[J]. Expert Rev Respir Med, 2011, 5(1): 9-16.
3Hogg JC. Pathophysiology of airtlow limitation inchronic obstructive pulmonary disease [J]. Lancet, 2004. 364(9435): 709-21.
4Hansel TF, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease [J]. Lancet, 2009, 374(9691): 744-55.
5Banles PJ. Mediators of chronic obstructive pulmonary disease[J]. Pharmacol Rev, 2004, 56(4): 515-48.
6Barnes PJ. Immunology of asthma and chronic obstruc- tive pulmonary disease [J]. Nat Rev hnmunol, 2008, 8 (3): 183-92.
7Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstruc- tive pulmonary disease: molecular and cellular mecha- nisms[J]. Eur Respir J, 2003, 22(4): 672-88.
8Jacobsen JR. ThiM-generation long-acting 2-adreno- ceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled 2-adrcno- ceptor agonists [J]. Future Med Chem, 2011, 3 (13): 1607-22.
9Waldeck B. Beta-adrenoceptor agonists and asthma-- 100 years of development [J]. Eur J Pharmacol, 2002. 445(1-2): 1-12.
10Baur F, Beattie D, Beer D, et al. The identification of indacalerol as an ultralong-aeting Inhaled 132-adreno- ceptor agonist[J]. J Med Chem, 2010, 53(9): 3675-84.